|
|
The Fourth Wave: A New Generation of Protein-Based TherapeuticsPublished by: Decision Resources Published: Aug. 10, 2006 - 22 Pages Price reduced due to age.Table of Contents
AbstractAlthough protein-based therapeutics were seen as a risky and diffi cult fi eld of endeavor, the biopharmaceutical industry's persistent pursuit of such agents created a multi-billion-dollar marketplace and a host of life-saving treatments. Now, as fi rst-generation drugs face patent expiry, the industry is pursuing technological and commercial opportunities that it hopes will yield the next generation of protein-based drugs, improving patient care and expanding market share.Get the Answers You Need to Shape Your Strategy Companies are developing technologies that will remodel recombinant protein and MAb therapeutics into next-generation drugs. What opportunities are being pursued for improving protein therapeutics? How will next-generation drugs improve upon their predecessors? Targeting protein therapeutics to reduce adverse side effects is an important goal and includes the creation of new classes of fusion proteins. Which companies are developing leading-edge technologies? What other advantages do targeted therapeutics hold? Researchers have developed promising new techniques for conjugating MAbs to various payloads, such as adding cytotoxic agents or radioisotopes to protein-based drugs. What are the advantages of these new protein conjugation techniques? Which companies lead the fi eld? Demand for protein therapeutics grows each year, but manufacturing therapeutic proteins remains expensive and time-consuming. How are companies reducing cost and the time needed to produce recombinant proteins? Which methods are most promising? Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||